SEC Form 4 · accession 0001127602-18-008815
BIOGEN INC. · BIIB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alfred Sandrock
Officer — EVP, Chief Medical Officer
Period of report
Feb 23, 2018
Accepted (ET)
Feb 27, 2018 · 6:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875045
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Feb 23, 2018 | S | 908 | $293.44 | D | 6,553 | D | |
| Common Stock | Feb 23, 2018 | M | 467 | $0.00 | A | 7,020 | D | |
| Common Stock | Feb 23, 2018 | F | 208 | $292.78 | D | 6,812 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF4 | $0.00 | Feb 23, 2018 | M | 467 | D | — | Feb 23, 2018 | Common Stock | 467 | 595 | D |
| Restricted Stock UnitF5,F4 | $0.00 | Feb 23, 2018 | J | 595 | D | — | Feb 23, 2018 | Common Stock | 595 | 0 | D |
Explanation of responses
- F1Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
- F2Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.
- F3This represents the weighted average price for shares sold at a range between $293.30 (low) and $294.00 (high).
- F4The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
- F5This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.